Viral Genetics Inc. is a company that discovers and develops drug compounds to treat diseases such as cancer, Lyme disease, and HIV. The company discovers and develops immune-based therapies for autoimmune diseases using their thymus nuclear protein compound (TNP).
Viral Genetics recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed by M. Karen Newell, PhD. This technology appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials.
Thymus Nuclear Protein (TNP) is the core of their initial approach to the development of immune-based therapies. The company’s lead product candidate is VGV-1. It is an investigational treatment for HIV/AIDS, consisting of TNP suspended in adjuvant. TNP proteins were originally studied as a means of early-detection of certain cancers.
In early pilot studies, the company learned that if the protein was introduced to an HIV-positive patient’s system along with adjuvant, over time an immuno-precipitation reaction gradually reappeared over approximately 8 weeks that was similar to an HIV-negative patient’s reaction. This was the start of their understanding the therapeutic potential of TNP. Consequently, this led directly to the company’s clinical development of VGV-1.
Viral Genetics, Inc. believes that VGV-1 represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, it focuses on boosting the immune system to allow the body to fight HIV more efficiently. Five human clinical trials have studied VGV-1 for the treatment of HIV/AIDS.
In May, Viral Genetics, Inc. announced that they were issued a patent for novel cancer therapies. The patent protects cancer drugs that have been tested in pre-clinical research studies in mice. Additional patents directed at generic classes of the drugs are still pending. The new therapies use metabolic disruption as a treatment of cancers, including multi-drug resistant cancers. This process is accomplished by the administration of 2-deoxy-D-glucose to inhibit high rate glucose metabolism, characteristic of cancer cells. The administration of 2-deoxy-D-glucose can be used in combination with current, standard chemotherapeutics and/or in combination with etomoxir, an inhibitor of fatty acid oxidation.
Let us hear your thoughts: Viral Genetics Inc. Message Board